<< Back
May 7, 2015 at 12:00 AM EDT

Cogentix Medical to Announce Fourth Quarter and Full Year Fiscal 2015 Results on May 14, 2015

Cogentix Medical to Announce Fourth Quarter and Full Year Fiscal 2015 Results on May 14, 2015

MINNEAPOLIS, MN, May 7, 2015 - Cogentix Medical, Inc. (NASDAQ: CGNT), a global medical device company primarily serving the urology market, will release financial results for the fourth quarter and fiscal year ended March 31, 2015 after the market close on Thursday, May 14, 2015.

The Company will host a conference call and webcast to discuss these results on Thursday, May 14, 2015 at 4:30 p.m. Eastern Time (3:30 p.m. Central Time). Rob Kill, President and Chief Executive Officer, and Brett Reynolds, Chief Financial Officer, will host the event. Individuals wishing to participate in the conference call should dial 888-539-3678. No passcode is necessary. To access a live webcast of the call, go to the investor relations section of Cogentix Medical's website at ir.cogentixmedical.com.

An audio replay will be available for 30 days following the call at 888-203-1112 with the passcode 3955010. An archived webcast will also be available at ir.cogentixmedical.com.

About Cogentix Medical Cogentix Medical, Inc., headquartered in Minnetonka, Minnesota, with operations in New York, Massachusetts, The Netherlands and the United Kingdom, is a global medical device company. We design, develop, manufacture and market products for flexible endoscopy with our unique product lines featuring a streamlined visualization system and proprietary sterile disposable microbial barrier, known as EndoSheath technology, providing users with efficient and cost effective endoscope turnover while enhancing patient safety. We also commercialize the Urgent® PC Neuromodulation System, an FDA-cleared device that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults. The symptoms include urinary urgency, frequency and urge incontinence. We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on Cogentix and our products, please visit us at www.cogentixmedical.com.

For Further Information: Cogentix Medical, Inc. Brett Reynolds, SVP and CFO 952-426-6152

EVC Group Doug Sherk/Brian Moore (Investors) 415-652-9100/310-579-6199